Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New TPO receptor agonists and their use as antithrombocytopenic agents

Oct. 29, 2003

Febuxostat in the treatment of gout and hyperuricemia

Oct. 29, 2003

Betagenon and AstraZeneca team up to tackle type 2 diabetes

Oct. 29, 2003

Studies support antiinflammatory, osteogenic and muscle-healing properties of BPC-157

Oct. 28, 2003

LibiGel meets endpoints in interim analysis of phase II trial for FSD

Oct. 28, 2003

Meiji Milk patent describes a cholesterol-lowering peptide

Oct. 28, 2003

Roche and Nippon Shinyaku to develop drugs for dyslipidemia

Oct. 27, 2003

Avandamet approved in E.U.

Oct. 27, 2003

Starlix approved in combination with TZD for type 2 diabetes

Oct. 27, 2003

Merck claims new androgen receptor modulators for osteoporosis and other disorders

Oct. 27, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...